敷尔佳：医用敷料领导者，积极变革迈向新程

Investment Rating - The report gives a "Buy" rating for the company, with a forecasted revenue of 1.791 billion, 2.074 billion, and 2.274 billion yuan for 2025, 2026, and 2027 respectively, and a net profit of 451 million, 524 million, and 576 million yuan for the same years [3]. Core Insights - The company has established a strong position in the medical dressing market through 30 years of development, focusing on high-quality growth and transformation [2][7]. - The company has built a comprehensive product matrix and sales channels, leveraging its first-mover advantage in the professional repair sector [2][3]. - The outlook for the company is positive, with expectations for long-term high-quality growth driven by product expansion and channel optimization [3]. Company Overview - Founded in 1996 as Huaxin Pharmaceutical, the company transitioned to skincare products in 2012 and established itself as a leading player in the medical beauty skincare sector [7][10]. - The company has undergone significant changes, including the establishment of a Shanghai R&D center and a Hangzhou operational subsidiary, to enhance its development towards high-quality growth [3][14]. - The management team, led by founder Zhang Liguo, has extensive experience in the pharmaceutical and skincare industries, ensuring strategic continuity and effective execution of growth plans [14][16]. Industry Overview - The professional skincare market is rapidly expanding, with the medical dressing segment expected to grow significantly due to increasing consumer awareness and demand for effective skincare solutions [42][44]. - The medical dressing market is projected to reach 253.8 billion yuan by 2026, with a growth rate of 22.08%, driven by the rising demand for post-surgical and skin repair products [44][45]. - The market for patch-type products is also expected to grow, with a forecasted size of 271.8 billion yuan by 2026, reflecting a 17.05% growth rate [44][46].